A5067980172- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Cervical Cancer and HPV Research
- Cancer Genomics and Diagnostics
- Cancer survivorship and care
- Immunotherapy and Immune Responses
- Estrogen and related hormone effects
- Endometriosis Research and Treatment
- Childhood Cancer Survivors' Quality of Life
- Cancer Risks and Factors
- Virus-based gene therapy research
- CRISPR and Genetic Engineering
- Intraperitoneal and Appendiceal Malignancies
- Colorectal and Anal Carcinomas
- Uterine Myomas and Treatments
- BRCA gene mutations in cancer
- Glioma Diagnosis and Treatment
- Renal cell carcinoma treatment
- Palliative Care and End-of-Life Issues
- Enhanced Recovery After Surgery
- Cancer-related cognitive impairment studies
- Colorectal Cancer Surgical Treatments
- Genetic factors in colorectal cancer
Oslo University Hospital
2016-2025
University of Oslo
2016-2025
Nordic Society of Gynecologic Oncology
2022-2024
Rigshospitalet
2024
Copenhagen University Hospital
2024
Norwegian Cancer Society
2016-2023
Stanford University
2023
International Federation of Gynaecology and Obstetrics
2023
OsloMet – Oslo Metropolitan University
2022
Massachusetts General Hospital
2022
Abstract Introduction Many advances in the understanding of pathologic and molecular features endometrial cancer have occurred since FIGO staging was last updated 2009. Substantially more outcome biological behavior data are now available regarding several histological types. Molecular genetic findings accelerated publication The Cancer Genome Atlas (TCGA) provide improved clarity on diverse nature this collection cancers their differing prognostic outcomes. goals new system to better define...
Introduction: Many advances in the understanding of pathologic and molecular features endometrial cancer have occurred since FIGO staging was last updated 2009.Substantially more outcome biological behavior data are now available regarding several histological types.Molecular genetic findings accelerated publication The Cancer Genome Atlas (TCGA) provide improved clarity on diverse nature this collection cancers their differing prognostic outcomes.The goals new system to better define these...
Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is the standard of care for some patients with advanced ovarian cancer. We evaluated efficacy and safety PARP rechallenge.
Receptor tyrosine kinases play an important role in malignant transformation of epithelial cells by activating signal transduction pathways for proliferation, invasion and metastasis. In a pilot study (n = 40), we evaluated expression the c-Met Her2/neu receptor ligand hepatocyte growth factor/scatter factor (HGF/SF) primary breast cancers their lymph node metastases using both conventional immunohistochemistry confocal immunofluorescence. Neither HGF/SF nor correlated with established...
ObjectiveThe phase IIIb OPINION trial (NCT03402841) investigated olaparib maintenance monotherapy in patients without a deleterious or suspected germline BRCA1/BRCA2 mutation (gBRCAm) who had platinum-sensitive relapsed ovarian cancer (PSROC) and received ≥2 previous lines of platinum-based chemotherapy.MethodsIn this single-arm, open-label, international study, responded to chemotherapy tablets (300 mg twice daily) until disease progression unacceptable toxicity. The primary endpoint was...
ObjectiveDespite its generally favorable prognosis at primary diagnosis, recurrence of endometrial cancer remains an important clinical challenge. The aim this study was to analyze the value molecular classification in recurrent cancer.MethodsThis included patients with who underwent surgical treatment between 2004 and 2015 Karolinska University Hospital, Sweden Bern Switzerland (KImBer cohort) tumor.ResultsOut 594 molecularly classified patients, 101 experienced recurrence, consisting 2...
This follow-up of a randomized study was conducted to assess the long-term effects external beam radiation therapy (EBRT) in adjuvant treatment early-stage endometrial cancer.Between 1968 and 1974, 568 patients with stage I cancer were included. After primary surgery, randomly assigned either vaginal radium brachytherapy followed by EBRT (n = 288) or alone 280). Overall survival analyzed using Kaplan-Meier method. A Cox proportional hazards model used estimate hazard ratios (HRs) 95% CIs. We...
Obesity increases the risk for a number of solid malignant tumours. However, it is not clear whether body mass index (BMI) and height are associated with primary tumours central nervous system (CNS). In large population study (The Nord–Trøndelag Health Study (HUNT Study)) 74 242 participants in Norway, weight were measured. During follow-up, incident CNS identified by individual linkage to Norwegian Cancer Registry. Sex- age-adjusted multivariable Cox regression analyses used evaluate BMI...
<h3>Importance</h3> Chemotherapy during the first trimester of pregnancy should be avoided owing to risk congenital malformations. However, precise gestational age at which chemotherapy can initiated safely remains unclear. <h3>Objective</h3> To assess malformation rates associated with initiation among pregnant women cancer. <h3>Design, Setting, and Participants</h3> This multicenter cohort study evaluated all who received between 1977 2019 registered in International Network on Cancer,...
LBA5501 Background: Paclitaxel or pegylated liposomal doxorubicin (PLD) in combination with bevacizumab (bev) are standard treatment options patients relapsed ovarian cancer not candidates for platinum, but responses usually short-lived. Recently, two trials have reported a numerical non-significant advantage from the addition of atezolizumab (atezo) to chemo plus bev recurrent setting (ATALANTE, Kurtz JE et al., J Clin Oncol & NRG GY009, O'Cearbhaill al, IGCS 2023). AGO-OVAR 2.29...
Abstract Introduction The incidence of cancer during pregnancy and within first year post‐delivery, ie pregnancy‐associated (PAC), is increasing in many countries, but little known about risk factors for these trends. This study quantified PAC by trimesters post‐delivery periods, assessed the role maternal age, parity, immigrant status, education, smoking body mass index trends PAC. Material methods We used data from national birth registers Sweden 1973–2017 to define a register‐based cohort...
Background Second-line treatment options for persistent, recurrent or metastatic (r/m) cervical cancer are limited. We investigated the safety, efficacy, and immunogenicity of therapeutic DNA-based vaccine VB10.16 combined with immune checkpoint inhibitor atezolizumab in patients human papillomavirus (HPV)16-positive r/m cancer. Patients methods This multicenter, single-arm, phase 2a study ( NCT04405349 , registered 26 May 2020) enrolled adult HPV16-positive received 3 mg (every weeks (Q3W)...